Cassava Sciences Valuation
Is SAVA * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SAVA * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SAVA *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SAVA *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SAVA *?
Other financial metrics that can be useful for relative valuation.
What is SAVA *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$1.05b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | -9.4x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does SAVA *'s PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.8x | ||
LAB B Genomma Lab Internacional. de | 1.7x | 28.6% | Mex$16.2b |
000915 Shandong Wit Dyne HealthLtd | 2.4x | 14.1% | CN¥7.5b |
300119 Tianjin Ringpu Bio-TechnologyLtd | 1.6x | 17.7% | CN¥7.4b |
600664 Harbin Pharmaceutical Group | 1.5x | n/a | CN¥7.4b |
SAVA * Cassava Sciences | 13.3x | 17.5% | Mex$1.0b |
Price-To-Book vs Peers: SAVA * is expensive based on its Price-To-Book Ratio (13.3x) compared to the peer average (1.8x).
Price to Earnings Ratio vs Industry
How does SAVA *'s PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?
Price-To-Book vs Industry: SAVA * is expensive based on its Price-To-Book Ratio (13.3x) compared to the Global Pharmaceuticals industry average (2x).
Price to Book Ratio vs Fair Ratio
What is SAVA *'s PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 13.3x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate SAVA *'s Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$369.98 | Mex$1,710.09 +362.2% | 27.2% | Mex$2,174.97 | Mex$1,245.21 | n/a | 2 |
May ’25 | n/a | Mex$1,698.08 0% | 24.6% | Mex$2,116.20 | Mex$1,279.96 | n/a | 2 |
Apr ’25 | n/a | Mex$1,698.08 0% | 24.6% | Mex$2,116.20 | Mex$1,279.96 | n/a | 2 |
Mar ’25 | n/a | Mex$1,698.08 0% | 24.6% | Mex$2,116.20 | Mex$1,279.96 | n/a | 2 |
May ’24 | n/a | Mex$1,364.73 0% | 63.2% | Mex$2,226.67 | Mex$502.80 | n/a | 2 |
Apr ’24 | n/a | Mex$1,364.73 0% | 63.2% | Mex$2,226.67 | Mex$502.80 | n/a | 2 |
Mar ’24 | Mex$490.00 | Mex$1,435.66 +193.0% | 63.2% | Mex$2,342.38 | Mex$528.93 | n/a | 2 |
Feb ’24 | Mex$525.00 | Mex$1,427.60 +171.9% | 63.2% | Mex$2,329.24 | Mex$525.96 | n/a | 2 |
Jan ’24 | n/a | Mex$1,147.65 0% | 79.5% | Mex$2,385.07 | Mex$211.58 | n/a | 3 |
Dec ’23 | Mex$650.00 | Mex$1,147.65 +76.6% | 79.5% | Mex$2,385.07 | Mex$211.58 | n/a | 3 |
Nov ’23 | Mex$730.00 | Mex$1,174.36 +60.9% | 82.6% | Mex$2,482.17 | Mex$160.14 | Mex$350.00 | 3 |
Oct ’23 | Mex$935.00 | Mex$1,180.30 +26.2% | 82.6% | Mex$2,494.73 | Mex$160.95 | n/a | 3 |
Sep ’23 | Mex$520.00 | Mex$1,180.30 +127.0% | 82.6% | Mex$2,494.73 | Mex$160.95 | n/a | 3 |
Aug ’23 | Mex$350.00 | Mex$1,286.10 +267.5% | 75.0% | Mex$2,518.06 | Mex$162.46 | n/a | 3 |
Jul ’23 | n/a | Mex$1,238.03 0% | 75.0% | Mex$2,423.94 | Mex$156.38 | n/a | 3 |
Jun ’23 | Mex$530.00 | Mex$1,275.24 +140.6% | 75.0% | Mex$2,496.78 | Mex$161.08 | Mex$430.00 | 3 |
May ’23 | Mex$430.00 | Mex$1,387.36 +222.6% | 69.8% | Mex$2,529.90 | Mex$163.22 | n/a | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.